Abstract: The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused by mycobacteria. The invention aims at the generation of a new series of benzothiazinone compounds having the potential to overcome the above mentioned problems. In a preferred embodiment the invention is concerned with compounds of the general formula (I) wherein R1 represents NO2, R2 represents CF3, at least one of the substituents R3 and R4 is OH, SR14, NHR15, CN, N3, a saturated or unsaturated, optionally halogenated, linear or branched aliphatic radical having 1-4 carbon atoms, linear or branched C1-C4 alkoxy, C1-C4 acyl, and the other of R3 and R4 may in addition be hydrogen, R6 represents a 2-methyl-1,4-dioxa-8-azaspiro[4.

Abstract: The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused by mycobacteria. The invention aims at the generation of a new series of benzothiazinone compounds having the potential to overcome the above mentioned problems. The invention is in a preferred embodiment concerned with compounds of the general formula (I), wherein the substituents R1 to R15 have the meanings as provided in claim 1 and depending claims.

Abstract: The present invention provides the in-vitro use of at least one in-vivo-target antigen of Aspergillus fumigatus for selective activation, detection and/or analysis of Aspergillus fumigatus specific CD4+ T cells in a sample comprising cells, wherein said at least one in-vivo-target antigen reveals an immune reactivity characterized by i) the in vivo existence of antigen-specific T cells comprising more than 60% memory T cells and ii) said antigen-specific T cells further comprise T cells able to produce IFN-gamma upon stimulation at a frequency between 15% and 80% and/or IL17 upon stimulation at a frequency between 5% and 30%. Said at least one in-vivo-target antigen may be selected from the group consisting of antigens Scw4, Pst1, Shm2, GliT and TpiA or fragments thereof. Also provided are a method, a composition, and a kit thereof.

Abstract: The present invention provides the in-vitro use of at least one in-vivo-target antigen of Aspergillus fumigatus for selective activation, detection and/or analysis of Aspergillus fumigatus specific CD4+ T cells in a sample comprising cells, wherein said at least one in-vivo-target antigen reveals an immune reactivity characterized by i) the in vivo existence of antigen-specific T cells comprising more than 60% memory T cells and ii) said antigen-specific T cells further comprise T cells able to produce IFN-gamma upon stimulation at a frequency between 15% and 80% and/or IL17 upon stimulation at a frequency between 5% and 30%. Said at least one in-vivo-target antigen may be selected from the group consisting of antigens Scw4, Pst1, Shm2, GliT and TpiA or fragments thereof. Also provided are a method, a composition, and a kit thereof.

Abstract: This invention relates to the field of biologically active compounds and specifically to phaeofungins, of the general formula (I) or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof, pharmaceutical compositions comprising these compounds, methods for the production of the phaeofungins and their use as fungicide, antibiotic as well as antitumor agent.

Abstract: This invention relates to the field of biologically active compounds and specifically to phaeofungins, of the general formula (I) or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof, pharmaceutical compositions comprising these compounds, methods for the production of the phaeofungins and their use as fungicide, antibiotic as well as antitumor agent.

Abstract: The invention relates to a method for producing a genetically modified organism of the Blakeslea genus, which method comprises the following steps (i) transformation of at least one of the cells, (ii) optional homokaryotic conversion of the cells obtained in step (i) to produce cells, in which one or more genetic characteristics of the nuclei are all modified in an identical manner and said modification manifests itself in the cells, and (iii) selection and cultivation of the genetically modified cell or cells.